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Abstract
Background:  Malignant Mesothelioma is a rare primary neoplasm affecting the serosal
membranes. During its relative short course, this malignant neoplasm can give local and, rarely,
distant haematogenous metastases in different organs. The reported metastatic sites include liver,
lung, heart, brain, thyroid, adrenals, kidneys, pancreas, bone, soft tissue, skin and lymph nodes.
Case Presentation: We report a sixty one year-old man with a history of malignant pleural
epithelioid mesothelioma treated with six cycles of Pemetrexed and Carboplatin completed 03/11/
04 followed by radiotherapy to the drain site 250 Kv/TD20Gy/5F completed 13/12/2004. Then he
developed multiple facial skin lesions 4 years later. These lesions were proved to be metastatic
malignant sarcomatoid mesothelioma.
Conclusion: Mesothelioma metastases should be suspected in any known Mesothelioma patient
with newly developed skin lesion.
Background
Malignant Mesothelioma is a rare primary neoplasm
affecting the serosal membranes. During its relative short
course, this malignant neoplasm can give local and,
rarely, distant haematogenous metastases in different
organs. The reported metastatic sites include liver, lung,
heart, brain, thyroid, adrenals, kidneys, pancreas, bone,
soft tissue, skin and lymph nodes. The increased incidence
of malignant mesothelioma and the improvement of sur-
vival rates due to the newly introduced chemotherapeutic
agents bring to light the importance of studying its
amended natural history.
Case Presentation
A 61 year-old white man with known history of pleural
mesothelioma on regular follow up was found to develop
multiple facial skin lesions with no clinical evidence of
local recurrence 4 years after the primary diagnosis.
On March 2004, this non-smoker, semi-retired boat
builder with significant asbestos exposure history, pre-
sented with 4 months history of progressive shortness of
breath. The inhalers had not helped and this seemed to be
clearly a different problem to his original asthma. He also
complained of some right chest pain, easy fatigue, dry
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cough and weight loss. On examination, there were only
signs of pleural effusion. The chest X-rays showed increas-
ing right pleural effusion and CT chest showed a large
right simple pleural effusion with no pleural thickening or
masses. He was admitted and the effusion drained. The
cytology of the effusion was highly suggestive of mesothe-
lioma, but pleural biopsy was insufficient. Few weeks
later, the pleural effusion recurred and an US guided
biopsy on 08/06/04 showed features consistent with a
malignant Mesothelioma, epithelioid type (Fig. 1). The
biopsy contains some skeletal muscle and some pleura
with a thick layer of malignant epithelioid cells which are
positive for mesothelial markers CK5/6 and Calretinin
and negative for lung cancer markers TTF-1 and CEA.
The patient took part on the ALIMTA trial, he received 6
cycles of Pemetrexed 500 mg/m2 + Carboplatin AUC 5 day
1 every 3 weeks; the last cycle date was 03/11/04. This was
followed by radiotherapy to the drain site "250 Kv/TD20
Gy/5F" completed 13/12/2004.
Then, the patient underwent close follow up and he
remained well and asymptomatic with no clinical or radi-
ological evidence of disease recurrence until the end of
December 2007, when he noticed small subcutaneous
lesion on his right check and some nasal symptoms. Few
weeks later, he developed fever 38°C with dry cough and
the cheek lesion increased in size. CT scan on 17/03/2008
recorded several sites of disease; notably in the right
hemithorax and right para-renal space consistent with
recurrence of the Mesothelioma. Clinical Examination of
the face revealed 3 skin lesions: right cheek 24 × 24 mm
Original pleural biopsy on June 2004, showing infiltration by  epithelioid tumour cells (a), which are positive with immuno- histochemical staining for Calretinin (b), consistent with epi- thelioid mesothelioma Figure 1
Original pleural biopsy on June 2004, showing infiltra-
tion by epithelioid tumour cells (a), which are posi-
tive with immunohistochemical staining for 
Calretinin (b), consistent with epithelioid mesotheli-
oma.
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Photos of skin lesion in the right cheek Figure 2
Photos of skin lesion in the right cheek.
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annular raised red area with eroded central area (Fig. 2), a
small erythematous plaque posterior to the right ear and
a 1 cm very firm subcutaneous lesion on the frontal area.
CT guided core biopsy from the right posterior basal pleu-
ral mass showed a thick layer of malignant epithelioid
cells. A panel of immunohistochemical markers were per-
formed and these malignant cells are positive for mes-
othelial markers CK5/6 and Calretinin and negative for
lung cancer markers TTF-1 and CEA. Overall, these fea-
tures are consistent with a malignant Mesothelioma, Epi-
thelioid type.
The three skin lesions were biopsied. The microscopic
examination showed sarcomatous atypical spindle cell
proliferation within the dermis extending into the subcu-
taneous adipose tissue (Fig. 3). Mitotic figures including
atypical forms are noted. The architecture of the tumour is
partly storiform. Immunohistochemistry showed positiv-
ity with Vimentin, CAM 5.2 and CD10 and focally with
SMA and Calretinin. The histopathological diagnosis was
in keeping with Metastatic Mesothelioma of sarcomatous
type.
Discussion
Malignant Mesothelioma is a rare primary neoplasm
affecting the serosal membranes with a relative increase of
its incidence rate during the last decades [1]. Most cases of
mesotheliomas are related to asbestos exposure [2]. Its
incidence has been rising steadily over the past few dec-
ades [1]. Approximately 1000 people die of mesotheli-
oma each year in the UK, and it is predicted to rise to 3000
by the year 2020 [3].
Histologically, Mesothelioma is divided into epithelial,
sarcomatous and mixed or biphasic subtypes. In several
series epithelial type has a significantly improved progno-
sis compared to sarcomatous variant [4]. The primary
diagnosis of our patient was epithelioid type; then the
local recurrence was also epithelioid, while the skin
metastases are of sarcomatous type; which may be
explained by the heterogeneous nature of the disease or
the known fact that malignant cells may loose some of
there differentiation when metastasis.
Systemic therapy is the only treatment option for the
majority of mesothelioma patients. For many years,
chemotherapy had a minimal impact on the natural his-
tory of this cancer. Countless drugs were evaluated, most
of which achieved response rates below 20% and median
survival of <1 year [5]. In recent years, there has been a
surge of optimism regarding systemic treatment of this
disease. Several cytotoxic agents have been shown to gen-
erate reproducible responses, improve quality of life, or
prolong survival in mesothelioma. Drugs with single-
agent activity include pemetrexed, raltitrexed, vinorel-
bine, and vinflunine [5]. The combination of pemetrexed
plus cisplatin is considered the benchmark front-line reg-
imen for this disease, based on a phase III trial in 456
patients that yielded a response rate of 41% and a median
survival of 12.1 months compared to 9.3 months for sin-
gle agent cisplatin [6]. A recent large International
Expanded Access Program confirmed the activity of peme-
trexed plus cisplatin and pemetrexed plus carboplatin in
chemonaive patients with Malignant Pleural Mesotheli-
oma, demonstrating clinically similar time to progressive
disease and 1-year survival rates [7]. Our patient received
6 cycles of Pemetrexed 500 mg/m2 +Carboplatin AUC 5
day 1 every 21 days, completed 03/11/04 with >37
months disease free survival. This long disease free sur-
vival in mesothelioma patients is rare; however this may
be explained by the small disease burden on primary pres-
entation and/or treatment received.
During its relative short course, this malignant neoplasm,
independently of the therapy, can give local or distant
haematogenous metastases in different organs. The
reported metastatic sites include liver, lung, heart, brain,
thyroid, adrenals, kidneys, pancreas, bone, soft tissue,
skin and lymph nodes [8,9].
Only small number of cases of subcutaneous metastases
of malignant Mesothelioma has been reported. However,
the majority of the reported cases were considered as local
invasion of the disease. To our knowledge, in English lan-
guage published articles, there are only 10 reported cases
of pleural Mesothelioma with distant subcutaneous
metastases [8,10-17]; seven of them had metastases to the
face and/or scalp. So, our case is the 11th reported pleural
Mesothelioma case with a distant subcutaneous metasta-
sis and it is the 8th case with face and/or scalp subcutane-
ous metastases [8,10-14].
Conclusion
With the increased incidence of malignant Mesothelioma
and the improvement of survival rates due to the newly
introduced chemotherapeutic agents, the number of
recorded distant skin metastases is likely to increase. Met-
astatic disease from mesothelioma should be suspected in
any known mesothelioma patient who develops a new
malignant skin lesion.World Journal of Surgical Oncology 2009, 7:84 http://www.wjso.com/content/7/1/84
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Skin biopsy on May 2008 showing dermal infiltration by a spindle cell tumour (a), which was positive with cytokeratin CAM5.2  immunohistochemical staining (b), and focally positive with Calretinin (c) and mesothelin (d) consistent with sarcomatoid mes- othelioma Figure 3
Skin biopsy on May 2008 showing dermal infiltration by a spindle cell tumour (a), which was positive with 
cytokeratin CAM5.2 immunohistochemical staining (b), and focally positive with Calretinin (c) and mesothelin 
(d) consistent with sarcomatoid mesothelioma.
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